公开(公告)号：US09642835B2

公开(公告)日：2017-05-09

申请号：US13867658

申请日：2013-04-22

Applicant: STC.UNM ,  University of Kansas

Inventor： Angela Wandinger-Ness ,  Larry Sklar ,  Zurab Surviladze ,  Tudor Oprea ,  Laurie Hudson ,  Jeffrey Aube ,  Jennifer E. Golden ,  Chad E. Schroeder ,  Denise S. Simpson ,  Julica J. Noth

IPC: A61K31/415 ,  A61K45/06 ,  C07D231/06 ,  A61K31/403 ,  A61K31/407

CPC classification number: A61K31/407 ,  A61K31/403 ,  A61K31/415 ,  A61K45/06 ,  C07D231/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/573 ,  Y02A50/473 ,  Y02A50/486 ,  A61K2300/00

Abstract: The present invention relates to molecules which function as selective modulators (i.e., inhibitors and agonists, preferably inhibitors) of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, where Cdc42 GTPase is overexpressed or hyperactivated, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role (e.g., neurodegenerative diseases), rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney diease, cystic kidney disease, precystic kidney disease and microbial infections. Additionally, compounds according to the present invention may be used to inhibit rejection (graft host response) in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.

公开(公告)号：US20170112912A1

公开(公告)日：2017-04-27

申请号：US15311298

申请日：2015-05-15

Applicant: STC.UNM

Inventor： Pavan MUTTIL ,  Denis WAFULA ,  Terry WU ,  Nitesh KUNDA ,  Dominique N. PRICE

IPC: A61K39/02 ,  A61K9/16

CPC classification number: A61K39/02 ,  A61K9/0075 ,  A61K9/1617 ,  A61K9/1623 ,  A61K2039/522 ,  A61K2039/545 ,  Y02A50/405

Abstract: This disclosure describes, generally, compositions and methods related to thermostable vaccine formulations, their storage, and their use. Generally, the thermostable vaccine formulations can be in the form of a dry powder. The dry powder formulations can increase the length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions.

公开(公告)号：US09630023B2

公开(公告)日：2017-04-25

申请号：US14107541

申请日：2013-12-16

Applicant: STC.UNM

Inventor： Shuang Luan ,  Nathan Swanson ,  Lijun Ma

IPC: A61B6/00 ,  A61N5/10 ,  A61B90/10 ,  A61B34/10

CPC classification number: A61N5/1031 ,  A61B34/10 ,  A61B90/10 ,  A61B2090/101 ,  A61N5/103 ,  A61N5/1042 ,  A61N5/1084

Abstract: The present invention is a method and system for developing a dynamic scheme for Gamma Knife radiosurgery based on the concept of “dose-painting” to take advantage of robotic patient positioning systems on the Gamma Knife C and Perfexion units. The spherical high dose volume created by the Gamma Knife unit will be viewed as a 3D spherical “paintbrush”, and treatment planning is reduced to finding the best route of this “paintbrush” to “paint” a 3D tumor volume. Under the dose-painting concept, Gamma Knife radiosurgery becomes dynamic, where the patient is moving continuously under the robotic positioning system.

公开(公告)号：US09623008B2

公开(公告)日：2017-04-18

申请号：US14793878

申请日：2015-07-08

Applicant: STC.UNM ,  UNIVERSITY OF MARYLAND, BALTIMORE

Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

IPC: A61K31/415 ,  C40B40/06 ,  A61K31/4184 ,  A61K31/165 ,  C12Q1/68 ,  G06F19/20 ,  A61K31/00

CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

公开(公告)号：US20170095550A1

公开(公告)日：2017-04-06

申请号：US15331155

申请日：2016-10-21

Applicant: STC.UNM

Inventor： Bryce C. Chackerian ,  David S. Peabody

IPC: A61K39/155 ,  C12N7/00 ,  C07K14/005

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/295 ,  A61K47/69 ,  A61K47/6901 ,  A61K47/6929 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55566 ,  A61K2039/6075 ,  C07K14/005 ,  C07K2319/40 ,  C12N7/00 ,  C12N2760/18523 ,  C12N2760/18534 ,  C12N2795/00023

Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection.

公开(公告)号：US09555583B1

公开(公告)日：2017-01-31

申请号：US14085671

申请日：2013-11-20

Applicant: Sandia Corporation ,  STC.UNM ,  Board of Regents, The University of Texas System

Inventor： Shawn M. Dirk ,  Stephen Buerger ,  Kirsten Nicole Cicotte ,  Elizabeth L. Dirk ,  Greg Reece ,  Patrick Lin

IPC: B29C67/00 ,  A61N1/05 ,  B33Y10/00 ,  A61B17/11

CPC classification number: B29C67/0062 ,  A61B17/1128 ,  A61B2017/00526 ,  A61N1/0551 ,  B33Y10/00

Abstract: The present invention is related to methods of fabricating neural interfaces using 3D projection micro-stereolithography.

Abstract translation: 本发明涉及使用3D投影微立体光刻技术制造神经接口的方法。

公开(公告)号：US20170011513A1

公开(公告)日：2017-01-12

申请号：US15274028

申请日：2016-09-23

Applicant: STC.UNM ,  SKINfrared LLC

Inventor： Sanjay Krishna ,  Sanchita Krishna ,  Majeed M. Hayat ,  Pradeep Sen ,  Maziar Yaesoubi ,  Sebastian Eugenio Godoy ,  Ajit Vijay Barve

IPC: G06T7/00 ,  G06K9/62 ,  G06F19/00 ,  G06K9/46

CPC classification number: G06T7/0012 ,  G06F19/00 ,  G06F19/321 ,  G06K9/46 ,  G06K9/4604 ,  G06K9/6267 ,  G06T3/00 ,  G06T3/0068 ,  G06T7/0016 ,  G06T7/30 ,  G06T7/337 ,  G06T2207/10024 ,  G06T2207/10048 ,  G06T2207/30088 ,  G06T2207/30096 ,  G06T2207/30204 ,  G16H50/20

Abstract: Apparatus and methods comprise examination of a subject using images of the subject. The images can provide a non-invasive analysis technique and can include a plurality of images of a portion of the subject at different times a temperature stimulus applied to the subject. An image of the portion of the subject can be aligned such that each pixel of the image corresponds to the same point on the subject over a sequence of images of the portion. The sequence of images can be processed after aligning the images such that data is extracted from the images. The extracted data can be used to make decisions regarding the health status of the subject. Additional apparatus, systems, and methods are disclosed.

Abstract translation: 装置和方法包括使用受试者的图像检查受试者。 图像可以提供非侵入性分析技术，并且可以在不同时间包括施加到对象的温度刺激的受试者的一部分的多个图像。 对象的部分的图像可以对准，使得图像的每个像素在该部分的图像序列上对应于被摄体上的相同点。 可以在对准图像之后处理图像序列，使得从图像中提取数据。 提取的数据可用于作出关于受试者的健康状况的决定。 公开了附加装置，系统和方法。

公开(公告)号：US09542198B2

公开(公告)日：2017-01-10

申请号：US14791627

申请日：2015-07-06

Applicant: STC.UNM

Inventor： Marios Stephanou Pattichis ,  Yuebing Jiang ,  Daniel Rolando Llamocca Obregon

IPC: G06F9/455 ,  G06F17/50 ,  G06F9/44 ,  H03H17/06 ,  H04N19/625 ,  H03H17/02

CPC classification number: G06F9/4401 ,  G06F17/5054 ,  G06F2217/08 ,  H03H17/0241 ,  H03H17/0294 ,  H03H17/06 ,  H04N19/625

Abstract: A dynamically reconfigurable framework manages processing applications in order to meet time-varying constraints to select an optimal hardware architecture. The optimal architecture satisfies time-varying constraints including for example, supplied power, required performance, accuracy levels, available bandwidth, and quality of output such as image reconstruction. The process of determining an optimal solution is defined in terms of multi-objective optimization using Pareto-optimal realizations.

Abstract translation: 动态可重构框架管理处理应用程序，以便满足时变约束以选择最佳硬件体系结构。 最优架构满足时变约束，包括例如所提供的功率，所需性能，精度水平，可用带宽以及诸如图像重建的输出质量。 确定最优解的过程是使用帕累托最优实现的多目标优化来定义的。

公开(公告)号：US09480653B2

公开(公告)日：2016-11-01

申请号：US14627739

申请日：2015-02-20

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Carlee Erin Ashley ,  Xingmao Jiang ,  Juewen Liu ,  David S. Peabody ,  Walker Richard Wharton ,  Eric Carnes ,  Bryce Chackerian ,  Cheryl L. Willman

IPC: A61K9/56 ,  A61K9/127 ,  A61K9/51 ,  A61K49/00 ,  A61K31/575 ,  A61K31/513 ,  A61K33/24 ,  A61K31/704

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/513 ,  A61K31/575 ,  A61K31/704 ,  A61K33/24 ,  A61K49/005

Abstract: Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.

公开(公告)号：US20160296588A1

公开(公告)日：2016-10-13

申请号：US15038557

申请日：2014-11-25

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K38/06 ,  A61K45/06 ,  A61K47/48

CPC classification number: A61K38/06 ,  A61K38/00 ,  A61K45/06 ,  C07K5/0823 ,  C07K14/7158

Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

Abstract translation: 本发明提供了一种基于CXCR拮抗肽的新型药物。 除其他之外，本发明提供用于治疗涉及CXCR介导的途径的疾病，病症和病症的肽，组合物和方法。 提供了有效治疗炎症，中风，创伤性脑损伤，胰腺癌等的组合物和方法。